2. Hemovigilance: A Quality Tool for the Blood Transfusion Chain

  1. René R. P. De Vries MD1 and
  2. Jean-Claude Faber MD2
  1. René R. P. de Vries MD

Published Online: 6 AUG 2012

DOI: 10.1002/9781118338179.ch2

Hemovigilance: An Effective Tool for Improving Transfusion Safety

Hemovigilance: An Effective Tool for Improving Transfusion Safety

How to Cite

de Vries, R. R. P. (2012) Hemovigilance: A Quality Tool for the Blood Transfusion Chain, in Hemovigilance: An Effective Tool for Improving Transfusion Safety (eds R. R. P. De Vries and J.-C. Faber), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781118338179.ch2

Editor Information

  1. 1

    Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands

  2. 2

    Blood Transfusion Service of the Luxembourg Red Cross, Luxembourg

Author Information

  1. Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands

Publication History

  1. Published Online: 6 AUG 2012
  2. Published Print: 29 AUG 2012

ISBN Information

Print ISBN: 9780470655276

Online ISBN: 9781118338179

SEARCH

Keywords:

  • hemovigilance, quality tool for blood transfusion chain;
  • history of blood transfusions;
  • hemovigilance, with several definitions existing;
  • plasma derivatives, as clotting factor concentrates, immunoglobulins;
  • hemovigilance, quality system for blood transfusion;
  • adverse event, undesirable in blood transfusion chain;
  • hemovigilance, quality management system for healthcare;
  • blood components;
  • donors, and adverse reactions or complications;
  • hemovigilance systems, at three levels

Summary

This chapter contains sections titled:

  • History of blood transfusions

  • Introducing hemovigilance

  • Hemovigilance in the blood establishment and the hospital: The blood transfusion chain (Part 2)

  • Establishing a hemovigilance system (Part 2, Section 2.1)

  • Hemovigilance systems at three levels (Parts 3 and 4)

  • Results and achievements (Part 5)

  • New developments: Vigilance of alternatives for and appropriateness of transfusion and tissue-/bio-vigilance (see Part 6)

  • References